A proven healthcare strategist with demonstrated fiscal and operational excellence in both traditional and nontraditional sectors.
Accurate #diagnosis for #dementia and #Alzheimers is critical for treatment. Learn how Mayo Clinic Laboratories is making an impact in this space. https://lnkd.in/gPJ7dj8j
Our latest paper is hot off the press! Please take a look at our paper in the link below. Microstructure proceeds macrostructure, and our technology, CDM, is able to show clinical utility in MCI patients who are #amyloid and #tau negative. #Alzheimersdisease #microstructure
🇬🇧 🇮🇹 We are very excited to share yet another paper this month. CDM demonstrates clinical utility with Mild Cognitively Impaired subjects who are #Amyloid and #Tau negative. A challenge for every #neurologist around the world who wants to understand more on differential diagnosis. Our results, once again, show that #microstructure as a measure of #neurodegeneration early in disease stage can play a vital role to support clincial decision making. Link below to our website to access the paper. https://lnkd.in/gDAP56w4 #dementia #alzheimersdisease #cortex #AAIC2024 #patientcare
absolutely love the findings in our latest paper. A busy period for us. valuable insights and impact on assessing patients in dementia and or any other neurological disorder. Love this paper. 🧡 #microstructure rocks !!!
🇬🇧 🇮🇹 We are very excited to share yet another paper this month. CDM demonstrates clinical utility with Mild Cognitively Impaired subjects who are #Amyloid and #Tau negative. A challenge for every #neurologist around the world who wants to understand more on differential diagnosis. Our results, once again, show that #microstructure as a measure of #neurodegeneration early in disease stage can play a vital role to support clincial decision making. Link below to our website to access the paper. https://lnkd.in/gDAP56w4 #dementia #alzheimersdisease #cortex #AAIC2024 #patientcare
For all the fantastic work in developing new therapies, early diagnosis remains a key factor in treating a lot conditions. One of the most stressful times for any patient is the "not knowing" stage. Finding out what is causing the issue and mapping out a treatment plan can bring a lot of positivity for patients. It is great to see new diagnosis methods being used in large scale trials that can help reduce this stage for patients. https://lnkd.in/e2qQ5PT6 #diagnosis #clinicaltrials #dementia #NHS
Join our upcoming webinar on Patient Centricity in Neurodegenerative Diseases on July 11th and learn how to integrate patient-centric approaches in clinical research. Neurodegenerative diseases have a profound impact on patients, caregivers, and healthcare systems. While advancements have been made, there's a critical need to amplify patient and caregiver voices throughout the research journey. This webinar brings together experts from pharma and patient advocacy groups to discuss: • Patient-centric precision medicine: • The crucial role of biomarkers in treatment development • Why patient & caregiver input matters in clinical trial design and execution Register now and ensure patients are at the forefront of research! #CNS #NeurodegenerativeDisorders #PatientCentricity #DigitalBiomarkers #ImagingBiomarkers #ClinicalTrialEndpoints #COA #Parkinsons #Alzheimers #ClinicalTrials #PrecisionMedicine
#PD #enhancedrehabilitationmatters #motoroutcome #exercise "We found that the subjects who underwent specialized enhanced rehabilitation had a better motor outcome over time than those who were managed by expert neurologists but had participated in community programs for exercise and other allied health interventions. The greatest effects were seen in patients in the early stages of the disease with a high amount of vigorous exercise per week in the last six months. Similar effects were seen for PDQ39, MCSI, the number of falls, and hospitalization. Conclusions: Long-term benefits to motor function and the quality of life in patients with PD and burden reduction in their caregivers can be achieved through a systematic program of specialized enhanced rehabilitation interventions."
Join our upcoming webinar on Patient Centricity in Neurodegenerative Diseases on July 11th and learn how to integrate patient-centric approaches in clinical research. Neurodegenerative diseases have a profound impact on patients, caregivers, and healthcare systems. While advancements have been made, there's a critical need to amplify patient and caregiver voices throughout the research journey. This webinar brings together experts from pharma and patient advocacy groups to discuss: • Patient-centric precision medicine • The crucial role of biomarkers in treatment development • Why patient & caregiver input matters in clinical trial design and execution Register now and ensure patients are at the forefront of research! https://lnkd.in/ehUt-mD7 #CNS #NeurodegenerativeDisorders #PatientCentricity #DigitalBiomarkers #ImagingBiomarkers #ClinicalTrialEndpoints #COA #Parkinsons #Alzheimers #ClinicalTrials #PrecisionMedicine
Join our upcoming webinar on Patient Centricity in Neurodegenerative Diseases on July 11th and learn how to integrate patient-centric approaches in clinical research. Neurodegenerative diseases have a profound impact on patients, caregivers, and healthcare systems. While advancements have been made, there's a critical need to amplify patient and caregiver voices throughout the research journey. This webinar brings together experts from pharma and patient advocacy groups to discuss: • Patient-centric precision medicine: • The crucial role of biomarkers in treatment development • Why patient & caregiver input matters in clinical trial design and execution Register now and ensure patients are at the forefront of research! https://lnkd.in/gB2Rydes #CNS #NeurodegenerativeDisorders #PatientCentricity #DigitalBiomarkers #ImagingBiomarkers #ClinicalTrialEndpoints #COA #Parkinsons #Alzheimers #ClinicalTrials #PrecisionMedicine
Who in healthcare hasn’t wanted to reduce the time it takes to arrive at a diagnosis for an anxious patient? It’s a common worry. That’s why research reported at the 2024 Alzheimer’s Association International Conference is attracting a lot of attention. Led by Soeren Mattke, M.D., D.Sc., Director of the Brain Health Observatory at the University of Southern California, the research highlights a blood test to help diagnose Alzheimer’s disease (AD) with a performance similar to C2N Diagnostics’ PrecivityAD2™ blood test. “Impact of a High-Performing Blood Test on Wait Times for Determination of Eligibility for a Disease-Modifying Alzheimer’s Treatment in the U.S.” focuses on the following: -The FDA has fully approved two disease-modifying treatments for AD management. Despite the availability of these agents, concerns have been raised about wait times in the patient diagnostic journey due to a limited number of AD specialists and PET scanners. -The study analysis showed substantial wait times in the diagnostic process. Projected wait times are estimated at 12 months in 2024 and expected to increase to over 100 months by 2033; almost all of the wait times are due to lack of AD specialist appointments. -A blood test to detect Alzheimer’s pathology in patients with early-stage cognitive impairment implemented in primary care is projected to reduce anticipated wait times substantially by prioritizing those with evidence for AD pathology for specialist visits. www.precivityAD.com #AAIC2024 #AAIC24 #Alzheimersdisease #AAICpostersession #clinicalwaittime #personalizedmedicine
Advocate for Brain Health and Caregivers, Applied AI, Women in Technology: Advancing Human Well-being through Strategic Alliances | Board Member
Promising! Conducting gentle non-invasive evaluations may enhance the accessibility of #Alzheimers diagnosis to a broader audience, paving the way for earlier initiation of therapy. This, in turn, has the potential to decelerate the condition's advancement and result in prolonged and healthier lifespans. - https://buff.ly/4e0SNZZ https://buff.ly/4e0SNZZ #EndAlz
Did you know that low-income countries have only 1 #neurologist per million people, while even high-income countries average just 71 per million? Timely care is crucial in #strokecare, but the shortage of specialists remains a significant challenge. #AI-powered Hub & Spoke networks are addressing both issues—reducing time to treatment and extending access to specialized care. By connecting tertiary hospitals to peripheral ones and optimizing #strokecare pathways, these networks are redefining stroke care. Check out our webinar on real-world evidence of AI-powered Hub & Spoke Stroke Care: https://lnkd.in/duU8-vyr
